Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized rituximab regimen for pemphigus
ChiCTR2200062766Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of rituximab in pemphigus (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Rate of complete remission at 12 months. Started Aug 2022; status: recruiting.
02
Drugs
rituximab
03
Conditions
pemphigus
Beyond the preview
Go deeper on ChiCTR2200062766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062766.